These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34536931)

  • 41. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
    Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
    Tang G; Kertesz DJ; Yang M; Lin X; Wang Z; Li W; Qiu Z; Chen J; Mei J; Chen L; Mirzadegan T; Harris SF; Villaseñor AG; Fretland J; Fitch WL; Hang JQ; Heilek G; Klumpp K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6020-3. PubMed ID: 20829038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
    Feng D; Zuo X; Jing L; Chen CH; Olotu FA; Lin H; Soliman M; De Clercq E; Pannecouque C; Lee KH; Kang D; Liu X; Zhan P
    Eur J Med Chem; 2021 Feb; 211():113063. PubMed ID: 33340914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yu M; Fan E; Wu J; Liu X
    Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
    Chen W; Zhan P; Daelemans D; Yang J; Huang B; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2016 Oct; 121():352-363. PubMed ID: 27267005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
    Gu SX; Qiao H; Zhu YY; Shu QC; Liu H; Ju XL; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2015 Oct; 23(20):6587-93. PubMed ID: 26385446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.
    Sang Y; Han S; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2019 Aug; 89():102974. PubMed ID: 31102693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
    Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
    Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
    Urano E; Miyauchi K; Kojima Y; Hamatake M; Ablan SD; Fudo S; Freed EO; Hoshino T; Komano J
    ChemMedChem; 2016 Oct; 11(20):2320-2326. PubMed ID: 27634404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Rai D; Chen W; Tian Y; Chen X; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem; 2013 Dec; 21(23):7398-405. PubMed ID: 24134904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
    Liang YH; He QQ; Zeng ZS; Liu ZQ; Feng XQ; Chen FE; Balzarini J; Pannecouque C; Clercq ED
    Bioorg Med Chem; 2010 Jul; 18(13):4601-5. PubMed ID: 20570527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and synthesis of Fsp
    Sang Z; Zhang T; Wang Z; De Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
    Chem Biol Drug Des; 2024 Mar; 103(3):e14510. PubMed ID: 38519265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I.
    Kang D; Wang Z; Chen M; Feng D; Wu G; Zhou Z; Jing L; Zuo X; Jiang X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Chem Biol Drug Des; 2019 Apr; 93(4):430-437. PubMed ID: 30381875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors.
    Wang Z; Kang D; Chen M; Wu G; Feng D; Zhao T; Zhou Z; Huo Z; Jing L; Zuo X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Chem Biol Drug Des; 2018 Dec; 92(6):2009-2021. PubMed ID: 30079476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.
    Arranz ME; Díaz JA; Ingate ST; Witvrouw M; Pannecouque C; Balzarini J; De Clercq E; Vega S
    Bioorg Med Chem; 1999 Dec; 7(12):2811-22. PubMed ID: 10658585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent HIV-1 NNRTIs with an Improved Drug Resistance Profile.
    Mao TQ; He QQ; Chen WX; Tang GF; Chen FE; De Clercq E; Daelemans D; Pannecouque C
    Curr Pharm Des; 2016; 22(46):6982-6987. PubMed ID: 27875973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.
    Huang B; Chen W; Zhao T; Li Z; Jiang X; Ginex T; Vílchez D; Luque FJ; Kang D; Gao P; Zhang J; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2019 Feb; 62(4):2083-2098. PubMed ID: 30721060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.